ABSTRACT
Although most well-differentiated gastric neuroendocrine tumors (gNETs) arise from enterochromaffin-like (ECL) cells in patients with autoimmune metaplastic atrophic gastritis (AMAG), the morphologic spectrum of these type 1 ECL-cell gNETs is not well defined. The extent of metaplastic progression in the background mucosa of AMAG patients with gNETs is likewise unclear. Here we report the histomorphology of 226 gNETs, including 214 type 1 gNETs (78 cases from 50 AMAG patients) pooled from a population with high AMAG prevalence. Most type 1 gNETs were ≤1.0 cm, of low grade, and multifocal, consistent with the results of previous reports. However, a high proportion (70/214, 33%) displayed unusual gNET morphologies not previously appreciated in AMAG patients. Unlike other type 1 gNETs with conventional neuroendocrine tumor morphologies, unconventional type 1 gNETs displayed cribriform networks of atrophic cells embedded within myxoid matrix (secretory-cribriform variant, 59%), sheets of deceptively bland discohesive cells resembling inflammatory infiltrates (lymphoplasmacytoid variant, 31%), or wreath-like arrangements of columnar cells wrapped around collagenous cores (pseudopapillary variant, 14%). Another unusual feature was that unconventional gNETs grew laterally within the mucosa (50/70, 71%) and were only rarely sampled from the submucosa (3/70, 4%). These features also differed from the conspicuous radial nodules (99/135, 73%) and frequent submucosal involvement (57/135, 42%) observed for conventional gNETs (P < .0001). Irrespective of morphology, type 1 gNETs were nearly always detected at first AMAG diagnosis (45/50, 90%) and tended to persist thereafter (34/43, 79%), despite similar clinical symptoms and laboratory values between AMAG patients with gNETs and those without. However, unlike AMAG patients without gNETs (n = 50), the background mucosa in patients with gNETs (n = 50) had already progressed to the morphologic equivalent of end-stage metaplasia (P < .0001). This included diffuse loss of parietal cells (92% vs 52%), complete intestinal metaplasia (82% vs 40%), and pancreatic metaplasia (56% vs 6%). Thus, type 1 ECL-cell gNETs are morphologically heterogeneous with a high prevalence of unconventional gNET morphologies. They tend to present silently at first AMAG diagnosis as multifocal lesions that persist within fields of mature metaplasia.
Subject(s)
Autoimmune Diseases , Gastritis, Atrophic , Neuroendocrine Tumors , Precancerous Conditions , Stomach Neoplasms , Humans , Enterochromaffin-like Cells/metabolism , Enterochromaffin-like Cells/pathology , Neuroendocrine Tumors/pathology , Autoimmune Diseases/diagnosis , Autoimmune Diseases/metabolism , Autoimmune Diseases/pathology , Gastritis, Atrophic/diagnosis , Gastritis, Atrophic/metabolism , Gastritis, Atrophic/pathology , Stomach Neoplasms/pathology , Precancerous Conditions/pathology , Metaplasia/pathology , Gastric Mucosa/pathologyABSTRACT
Huntingtin-associated protein 1 (HAP1) is a neuronal cytoplasmic protein that is predominantly expressed in the brain and spinal cord. In addition to the central nervous system, HAP1 is also expressed in the peripheral organs including endocrine system. Different types of enteroendocrine cells (EEC) are present in the digestive organs. To date, the characterization of HAP1-immunoreactive (ir) cells remains unreported there. In the present study, the expression of HAP1 in pyloric stomach in adult male rats and its relationships with different chemical markers for EEC [gastrin, marker of gastrin (G) cells; somatostatin, marker of delta (D) cells; 5-HT, marker of enterochromaffin (EC) cells; histamine, marker of enterochromaffin-like (ECL) cells] were examined employing single- or double-labelled immunohistochemistry and with light-, fluorescence- or electron-microscopy. HAP1-ir cells were abundantly expressed in the glandular mucosa but were very few or none in the surface epithelium. Double-labelled immunofluorescence staining for HAP1 and markers for EECs showed that almost all the G-cells expressed HAP1. In contrast, HAP1 was completely lacking in D-cells, EC-cells or ECL-cells. Our current study is the first to clarify that HAP1 is selectively expressed in G-cells in rat pyloric stomach, which probably reflects HAP1's involvement in regulation of the secretion of gastrin.
Subject(s)
Enterochromaffin Cells/metabolism , Enterochromaffin-like Cells/metabolism , Gastric Mucosa/metabolism , Nerve Tissue Proteins/genetics , Pylorus/metabolism , Somatostatin-Secreting Cells/metabolism , Animals , Biomarkers/metabolism , Enterochromaffin Cells/cytology , Enterochromaffin-like Cells/cytology , Gastric Mucosa/cytology , Gastrins/biosynthesis , Gene Expression , Histamine/biosynthesis , Immunohistochemistry , Male , Nerve Tissue Proteins/metabolism , Organ Specificity , Pylorus/cytology , Rats , Rats, Wistar , Somatostatin/biosynthesis , Somatostatin-Secreting Cells/cytologyABSTRACT
BACKGROUND: Acid inhibition from chronic proton pump inhibitor use and a possible increase in gastrin can lead to changes in the regulation of hydrochloric acid production. However, it has not known whether such chronic use changes the presence of gastrin, delta, and enterochromaffin-like cells in the stomach or the relationship between gastrin and delta cells. AIM: To analyze the number of gastrin-producing gastrin cells, somatostatin-producing cells, and histamine-producing cells in patients who were chronic users of proton pump inhibitor, with or without related Helicobacter pylori infection. METHODS: Biopsies from 105 patients, including 81 chronic proton pump inhibitor users (experimental group) and 24 controls, were processed immunohistochemically and subjected to counting of gastrin, delta, and enterochromaffin-like cells in high-magnification microscopic fields and in 10 glands. RESULTS: Gastrin cell, delta cell, and enterochromaffin-like cells counts were similar across the groups and appeared to be unaffected by Helicobacter pylori infection. The ratio between gastrin cells and delta cells was higher in the chronic users of proton pump inhibitor group than in controls. CONCLUSION: Chronic users of proton pump inhibitor does not affect gastrin cell, delta cell, and enterochromaffin-like cell counts significantly, but may alter the ratio between gastrin cells and delta cells.
Subject(s)
Enterochromaffin-like Cells/metabolism , Gastrins/blood , Helicobacter Infections/therapy , Helicobacter pylori/isolation & purification , Proton Pump Inhibitors/therapeutic use , Proton Pumps/metabolism , Stomach Diseases/chemically induced , Case-Control Studies , Enterochromaffin-like Cells/drug effects , Gastrins/physiology , Helicobacter Infections/diagnosis , Humans , Proton Pump Inhibitors/adverse effects , Stomach , Stomach Diseases/bloodABSTRACT
Studies on the regulation of gastric acid secretion started more than 100 years ago at an early phase of experimental physiology. In nearly the whole last century there were disputes about the interpretation of the findings: the interaction between the three principle gastric acid secretagogues acetylcholine, gastrin and histamine, the cell producing the relevant histamine which turned out to be the ECL cell, the ability of the ECL cell to divide and thus develop into tumours, the classification of gastric carcinomas and the mechanism for Helicobacter pylori carcinogenesis. The elucidation of the central role of the ECL cell and thus its main regulator, gastrin, solve all these controversies, and gives a solid base for handling upper gastrointestinal diseases.
Subject(s)
Enterochromaffin-like Cells/metabolism , Gastric Acid/metabolism , Gastric Mucosa/metabolism , Gastrins/metabolism , Stomach Neoplasms/metabolism , Animals , Carcinogenesis , Enterochromaffin-like Cells/pathology , Gastric Mucosa/pathology , Helicobacter pylori , Humans , Stomach Neoplasms/pathologyABSTRACT
BACKGROUND & AIMS: Enterochromaffin-like (ECL) cells in the stomach express gastrin/cholecystokinin 2 receptor CCK2R and are known to expand under hypergastrinemia, but whether this results from expansion of existing ECL cells or increased production from progenitors has not been clarified. METHODS: We used mice with green fluorescent protein fluorescent reporter expression in ECL cells (histidine decarboxylase [Hdc]-green fluorescent protein), as well as Cck2r- and Hdc-driven Tamoxifen inducible recombinase Cre (Cck2r-CreERT2, Hdc-CreERT2) mice combined with Rosa26Sor-tdTomato (R26-tdTomato) mice, and studied their expression and cell fate in the gastric corpus by using models of hypergastrinemia (gastrin infusion, omeprazole treatment). RESULTS: Hdc-GFP marked the majority of ECL cells, located in the lower third of the gastric glands. Hypergastrinemia led to expansion of ECL cells that was not restricted to the gland base, and promoted cellular proliferation (Ki67) in the gastric isthmus but not in basal ECL cells. Cck2r-CreERT2 mice marked most ECL cells, as well as scattered cell types located higher up in the glands, whose number was increased during hypergastrinemia. Cck2r-CreERT2+ isthmus progenitors, but not Hdc+ mature ECL cells, were the source of ECL cell hyperplasia during hypergastrinemia and could grow as 3-dimensional spheroids in vitro. Moreover, gastrin treatment in vitro promoted sphere formation from sorted Cck2r+Hdc- cells, and increased chromogranin A and phosphorylated- extracellular signal-regulated kinase expression in CCK2R-derived organoids. Gastrin activates extracellular signal-regulated kinase pathways in vivo and in vitro, and treatment with the Mitogen-activated protein kinase kinase 1 inhibitor U0126 blocked hypergastrinemia-mediated changes, including CCK2R-derived ECL cell hyperplasia in vivo as well as sphere formation and chromogranin A expression in vitro. CONCLUSIONS: We show here that hypergastrinemia induces ECL cell hyperplasia that is derived primarily from CCK2R+ progenitors in the corpus. Gastrin-dependent function of CCK2R+ progenitors is regulated by the extracellular signal-regulated kinase pathway.
Subject(s)
Enterochromaffin-like Cells/pathology , Gastric Mucosa/pathology , Gastrins/blood , Animals , Disease Models, Animal , Enterochromaffin-like Cells/metabolism , Gastric Mucosa/cytology , Gastric Mucosa/metabolism , Gastrins/metabolism , Humans , Hyperplasia/blood , Hyperplasia/pathology , MAP Kinase Signaling System , Mice , Receptor, Cholecystokinin B/metabolism , Stem Cells/pathologyABSTRACT
BACKGROUND/AIMS: Although gastric atrophy is primarily caused by Helicobacter pylori infection, it is unclear why patients serologically diagnosed with gastric atrophy without H. pylori infection exhibit greater atrophy. We investigated histopathological features in serologically diagnosed gastric atrophy without H. pylori infection. METHODS: Thirty-four patients with positive serum pepsinogen and negative serum H. pylori antibody tests underwent gastric biopsy and histological evaluation. The presence of enterochromaffin-like cells (ECL) was also evaluated. Gastric cancer risks for each histological feature according to the Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia (OLGIM) were assessed. RESULTS: Twenty-five (74%) patients had histological gastric atrophy. Among those, the following histological subgroups were identified: eight had H. pylori but no ECL, 13 had neither H. pylori nor ECL, and 4 had ECL without H. pylori. Nine patients without histological atrophy had neither H. pylori nor ECL. Patients with H. pylori on histological diagnosis had significantly higher scores on OLGA and OLGIM. CONCLUSIONS: Various histological features, with significant differences in gastric cancer risk, were identified in the gastric mucosa serologically diagnosed with atrophy without H. pylori infection. Therefore, serological screening for gastric cancer risk tests has several limitations, and additional evaluations should be considered.
Subject(s)
Enterochromaffin-like Cells/metabolism , Gastric Mucosa/pathology , Gastritis, Atrophic/pathology , Precancerous Conditions/pathology , Stomach Neoplasms/diagnosis , Adult , Aged , Biopsy , Early Detection of Cancer , Female , Gastritis, Atrophic/diagnosis , Humans , Male , Metaplasia , Middle Aged , Precancerous Conditions/diagnosis , Randomized Controlled Trials as Topic , Risk Factors , Stomach Neoplasms/pathologyABSTRACT
ABSTRACT Background: Acid inhibition from chronic proton pump inhibitor use and a possible increase in gastrin can lead to changes in the regulation of hydrochloric acid production. However, it has not known whether such chronic use changes the presence of gastrin, delta, and enterochromaffin-like cells in the stomach or the relationship between gastrin and delta cells. Aim: To analyze the number of gastrin-producing gastrin cells, somatostatin-producing cells, and histamine-producing cells in patients who were chronic users of proton pump inhibitor, with or without related Helicobacter pylori infection. Methods: Biopsies from 105 patients, including 81 chronic proton pump inhibitor users (experimental group) and 24 controls, were processed immunohistochemically and subjected to counting of gastrin, delta, and enterochromaffin-like cells in high-magnification microscopic fields and in 10 glands. Results: Gastrin cell, delta cell, and enterochromaffin-like cells counts were similar across the groups and appeared to be unaffected by Helicobacter pylori infection. The ratio between gastrin cells and delta cells was higher in the chronic users of proton pump inhibitor group than in controls. Conclusion: Chronic users of proton pump inhibitor does not affect gastrin cell, delta cell, and enterochromaffin-like cell counts significantly, but may alter the ratio between gastrin cells and delta cells.
RESUMO Racional: A inibição ácida pelo uso crônico de inibidores de bomba de prótons e o possível aumento da gastrina podem ser seguidos de alterações na regulação da produção do ácido clorídrico. Ainda não está definido se o uso crônico altera a quantidade de células G, D e ECL no estômago ou a razão células G/D. Objetivo: Avaliar o número de células G - produtoras de gastrina -, células D - produtoras de somatostatina - e células ECL - produtoras de histamina -, em pacientes com uso crônico de inibidores de bomba de prótons, com ou sem infecção pelo Helicobacter pylori. Método: Trata-se de estudo retrospectivo avaliando 105 pacientes, 81 usadores crônicos de inibidores de bomba de prótons e 24 controles, através de biópsias com contagem das células G, D e ECL por estudo imunoistoquímico, de forma quantitativa onde havia maior número de células positivas por campo microscópico de grande aumento e em 10 glândulas. Resultados: Não houve diferença estatística comparando-se o número de células G, D e ECL. A razão entre as células G e D foi maior nos pacientes usadores crônicos de inibidores de bomba de prótons. Conclusão: O uso crônico de inibidores de prótons parece não interferir na contagem das células G, D e ECL, porém, interfere na razão entre as células G e D.
Subject(s)
Humans , Stomach Diseases/chemically induced , Gastrins/blood , Helicobacter pylori/isolation & purification , Helicobacter Infections/therapy , Proton Pumps/metabolism , Enterochromaffin-like Cells/metabolism , Proton Pump Inhibitors/therapeutic use , Stomach , Stomach Diseases/blood , Gastrins/physiology , Case-Control Studies , Helicobacter Infections/diagnosis , Enterochromaffin-like Cells/drug effects , Proton Pump Inhibitors/adverse effectsABSTRACT
Gastric cancer, a disease with a reduced frequency for decades, now appears to be on the rise again in young Americans. The epidemiology of gastric cancer differs between tumors in the cardia and those of the more distal parts of the stomach. The tumors are divided into the intestinal type showing glandular growth pattern and the diffuse type with a different pattern. The latter often expresses neuroendocrine and more specifically ECL-cell markers suggesting that they originate from the ECL cell, the target cell for the antral hormone, gastrin. Helicobacter pylori gastritis is accepted as the major cause of gastric cancer, but only after having induced oxyntic atrophy which reduces gastric acid secretion and thus induces hypoacidity leading to hypergastrinemia. Long-term hypergastrinemia is known to induce malignant neoplasia in the stomach of animals as well as man. Recently treatment with proton pump inhibitor after Helicobacter pylori eradication in patients with gastroesophageal reflux disease, has been reported to predispose to gastric cancer. Since profound acid inhibition is a well-known cause of gastric neoplasia, it is to be expected that Helicobacter pylori infection and profound acid inhibition has an additive or possibly potentiating effect on the development of gastric cancer.
Subject(s)
Gastrins/blood , Gastritis/microbiology , Gastroesophageal Reflux/pathology , Helicobacter Infections/pathology , Stomach Neoplasms/pathology , Animals , Enterochromaffin-like Cells/metabolism , Enterochromaffin-like Cells/pathology , Gastroesophageal Reflux/drug therapy , Helicobacter pylori/pathogenicity , Humans , Proton Pump Inhibitors/pharmacology , Stomach Neoplasms/classificationABSTRACT
BACKGROUND: Studies on the regulation of gastric and pancreatic secretion began more than 100 years ago. Secretin was the first hormone postulated to exist, initiating the field of endocrinology. Gastrin produced in the antral mucosa was the second postulated hormone, and together with histamine and acetylcholine, represent the three major gastric acid secretagogues known since 1920. For a long time, the mast cell was the only recognized histamine-producing cell in the oxyntic mucosa and, in the mid-1980s, the ECL cell was recognized as the cell producing histamine, taking part in the regulation of gastric acid secretion. METHODS: This review is based upon literature research and personal knowledge. RESULTS: The ECL cell carries the gastrin receptor, and gastrin regulates its function (histamine release) as well as proliferation. Long-term hypergastrinemia results in gastric neoplasia of variable malignancies, implying that gastric hypoacidity resulting in increased gastrin release will induce gastric neoplasia, including gastric cancer. CONCLUSIONS: The trophic effect of gastrin on the ECL cell has implications to the treatment with inhibitors of acid secretion.
Subject(s)
Enterochromaffin-like Cells/metabolism , Gastric Mucosa/metabolism , Gastrins/metabolism , Acetylcholine/metabolism , Animals , Enterochromaffin-like Cells/pathology , Gastric Mucosa/pathology , Histamine/metabolism , Humans , Receptor, Cholecystokinin B/metabolismABSTRACT
Adenosine is readily available to the glandular epithelium of the stomach. Formed continuously in intracellular and extracellular locations, it is notably produced from ATP released in enteric cotransmission. Adenosine analogs modulate chloride secretion in gastric glands and activate acid secretion in isolated parietal cells through A2B adenosine receptor (A2BR) binding. A functional link between surface A2BR and adenosine deaminase (ADA) was found in parietal cells, but whether this connection is a general feature of gastric mucosa cells is unknown. Here we examine whether A2BR is expressed at the membrane of histamine-producing enterochromaffin-like (ECL) cells, the major endocrine cell type in the oxyntic mucosa, and if so, whether it has a vicinity relationship with ADA. We used a highly homogeneous population of rabbit ECL cells (size 7.5-10 µm) after purification by elutriation centrifugation. The surface expression of A2BR and ADA proteins was assessed by flow cytometry and confocal microscopy. Our findings demonstrate that A2BR and ADA are partially coexpressed at the gastric ECL cell surface and that A2BR is functional, with regard to binding of adenosine analogs and adenylate cyclase activation. The physiological relevance of A2BR and ADA association in regulating histamine release is yet to be explained.
Subject(s)
Adenosine Deaminase/genetics , Enterochromaffin-like Cells/metabolism , Gastric Mucosa/cytology , Gastric Mucosa/metabolism , Gene Expression , Receptor, Adenosine A2B/genetics , Adenosine Deaminase/metabolism , Animals , Biomarkers , Flow Cytometry , Rabbits , Receptor, Adenosine A2B/metabolismABSTRACT
BACKGROUND: Gastrin, from G-cells, and histamine, from enterochromaffin-like (ECL) cells, are two of the hormones that regulate gastric activity. DISCUSSION: It is proposed that the G-cells and the ECL cells are coupled by the couplet molecules gastrin and histamine and by a prior asymmetrical cell division. The gastrin (from G-cells) stimulates the ECL cells to produce and secrete histamine while, in a reciprocal way, this histamine (from ECL cells), stimulates the G-cells to produce and secrete gastrin. These molecules would also stimulate cell division - the gastrin would stimulate cell division of ECL cells while histamine would stimulate that of G-cells. A chemical complex of gastrin and histamine is postulated as is also the asymmetric cell divisions of precursor cells to produce the coupled G-cells and ECL cells. CONCLUSION: There is sufficient evidence to support the feasibility of the model in general, but more direct experimental evidence is required to validate the model as applied here to gastric function.
Subject(s)
Enterochromaffin-like Cells/metabolism , Gastrin-Secreting Cells/metabolism , Helicobacter pylori/metabolism , Models, Biological , Stomach/cytology , Animals , Cell Division/physiology , Digestion/physiology , Gastrins/metabolism , Histamine Release/physiology , Humans , RatsABSTRACT
OBJECTIVE: Gastric carcinoids (neuroendocrine tumors) arise from enterochromaffin-like cells in the gastric mucosa. Most are caused by hypergastrinemia. The objectives were to determine if their prevalence in Europe, USA and Japan meets the criteria for an orphan disease and to justify treatment with a gastrin/CCK2 receptor antagonist. METHODS: We obtained data from European and USA cancer registries, and searched PubMed. RESULTS: Prevalence per 10,000 population obtained from cancer registries was: median 0.32 (range 0.09-0.92) for Europe; and 0.17 for the USA, equivalent to 4812 for the whole population. A PubMed search for gastric carcinoids yielded prevalence for Japan only, which was 0.05 per 10,000 population, equivalent to 665 for the entire population. A further search for gastric carcinoids in patients with pernicious anemia (PA) or autoimmune chronic atrophic gastritis (CAG), two presentations of about 80% of gastric carcinoids, produced prevalence rates of 5.2-11%. Prevalence of PA itself was 0.12-1.9%. Data on CAG epidemiology were sparse. CONCLUSION: Prevalence of gastric carcinoids varied widely. All sources probably underestimate prevalence. However, prevalence was below the limits required for recognition by drug regulatory authorities as an orphan disease: 5 per 10,000 population of Europe; 200,000 for the whole population of the USA; and 50,000 for the whole population of Japan. Because gastric carcinoids are an orphan disease, and nonclinical and healthy volunteer studies support treatment with netazepide, a gastrin/CCK2 antagonist, netazepide has been designated an orphan medicinal product in Europe and the USA for development as targeted treatment for gastric carcinoids.
Subject(s)
Benzodiazepinones/therapeutic use , Carcinoid Tumor/drug therapy , Carcinoid Tumor/epidemiology , Gastrointestinal Neoplasms/drug therapy , Gastrointestinal Neoplasms/epidemiology , Phenylurea Compounds/therapeutic use , Receptor, Cholecystokinin B/antagonists & inhibitors , Aged , Aged, 80 and over , Anemia, Pernicious/epidemiology , Enterochromaffin-like Cells/metabolism , Europe/epidemiology , Female , Gastric Mucosa/metabolism , Gastritis, Atrophic/epidemiology , Humans , Japan/epidemiology , Male , Prevalence , Rare Diseases , Sex Distribution , United States/epidemiologyABSTRACT
Transient receptor potential A1 (TRPA1) is widely expressed throughout the human and animal organism, including the dorsal root ganglia as well as the bladder, stomach and small intestine. Here, we examined the effect of three platelet aggregation inhibitors on TRPA1: ticlopidine, clopidogrel and prasugrel. Utilising fluorometric Ca(2+) influx analysis and electrophysiological whole cell measurements in TRPA1-expressing HEK293 and in human enterochromaffin-like QGP-1 cells, we found that ticlopidine, clopidogrel and prasugrel are direct activators of TRPA1. Although this polymodal channel commonly contributes to the perception of pain, temperature and chemical irritants, recent studies provide evidence for its involvement in the release of serotonin (5-HT) from enterochromaffin cells. Therefore, we further investigated the ability of ticlopidine, clopidogrel and prasugrel to stimulate 5-HT release from QGP-1 cells. We could determine 5-HT in supernatants from cultured QGP-1 cells upon treatment with ticlopidine and clopidogrel but not with prasugrel. These findings indicate that a robust TRPA1 activation by ticlopidine and clopidogrel correlates with the stimulatory effect on the secretion of 5-HT. As recipients of ticlopidine and clopidogrel frequently complain about gastrointestinal adverse events such as nausea, vomiting and diarrhoea, an activation of TRPA1 may contribute to adverse effects of such drugs in the digestive system.
Subject(s)
Calcium Channels/metabolism , Gene Expression Regulation/drug effects , Nerve Tissue Proteins/metabolism , Platelet Aggregation Inhibitors/pharmacology , Pyridines/pharmacology , Transient Receptor Potential Channels/metabolism , Calcium/metabolism , Calcium Channels/genetics , Cell Line , Clopidogrel , Enterochromaffin-like Cells/drug effects , Enterochromaffin-like Cells/metabolism , HEK293 Cells , Humans , Mutation , Nerve Tissue Proteins/genetics , Piperazines/chemistry , Piperazines/pharmacology , Platelet Aggregation Inhibitors/chemistry , Prasugrel Hydrochloride , Pyridines/chemistry , Serotonin/metabolism , TRPA1 Cation Channel , Thiophenes/chemistry , Thiophenes/pharmacology , Ticlopidine/analogs & derivatives , Ticlopidine/chemistry , Ticlopidine/pharmacology , Time-Lapse Imaging , Transient Receptor Potential Channels/geneticsABSTRACT
AIMS: To assess synaptophysin expression in columnar-lined oesophageal mucosa showing either goblet cells, known as intestinal metaplasia, or with accompanying oxyntic glands or pyloric glands. METHODS AND RESULTS: Of 159 biopsies, 53 were oesophageal (19 had intestinal metaplasia, 13 oxyntic glands, and 21 pyloric glands), 77 gastric (12 had goblet cells and 27 no goblet cells) and 29 duodenal. Synaptophysin-positive goblet cells were found in all biopsies from the normal duodenum, in 53% of the oesophageal biopsies showing intestinal metaplasia, but only in 8% of gastric biopsies showing intestinal metaplasia. Synaptophysin-positive Paneth cells occurred in all duodenal biopsies, and in nine of the gastric biopsies showing intestinal metaplasia, but in only one of the oesophageal biopsies showing intestinal metaplasia. A continuous synaptophysin-positive neck cell zone was found in all biopsies from the normal antrum, but in none of the oesophageal biopsies with pyloric glands or with chronic antritis. CONCLUSIONS: The paucity or absence of synaptophysin-positive cells in all three phenotypes of Barrett's mucosa might mirror a sequela of chronic inflammation caused by the particular pathogenic bacteria present in the immediate oesophageal microenvironment.
Subject(s)
Barrett Esophagus/metabolism , Barrett Esophagus/pathology , Synaptophysin/metabolism , Barrett Esophagus/etiology , Duodenum/metabolism , Duodenum/pathology , Enterochromaffin-like Cells/metabolism , Enterochromaffin-like Cells/pathology , Gastric Mucosa/metabolism , Gastric Mucosa/pathology , Goblet Cells/metabolism , Goblet Cells/pathology , Humans , Immunohistochemistry , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Metaplasia , Paneth Cells/metabolism , Paneth Cells/pathology , Parietal Cells, Gastric/metabolism , Parietal Cells, Gastric/pathologyABSTRACT
The stomach is innervated by the vagal nerve. Several studies have demonstrated that the vagal nerve has a trophic effect on the rat oxyntic mucosa and that the trophic effect of hypergastrinemia is dependent on intact vagal innervation. The effect of vagal denervation on gastric carcinogenesis has been examined in Mastomys natalensis and hypergastrinemic transgenic INS-GAS mice, with no effect of unilateral vagotomy in Mastomys but an anti-carcinogenic effect in INS-GAS mice. A proportion of female Japanese cotton rats develop spontaneous hypergastrinemia and ECL cell derived gastric carcinomas. In the current study we have examined the effects of unilateral anterior subdiaphragmatic vagotomy on gastric carcinogenesis. Female Japanese cotton rats were operated with unilateral anterior vagotomy or sham-operation at age 2 months and were terminated at age 10 months. Ten of fifteen animals operated by anterior vagotomy and 11 of 16 sham-operated developed hypergastrinemia. Vagotomy did not affect intragastric pH or serum gastrin. When comparing the anterior and posterior sides of the stomachs, vagotomy did not affect the occurrence of dysplasia or carcinoma development in the oxyntic mucosa. However, vagotomy resulted in lower stomach weight and reduced oxyntic mucosal thickness on the anterior side. Vagotomy also resulted in a reduction in volume density of chromogranin A positive cells in the oxyntic mucosa. In conclusion, vagotomy reduced the trophic effects of hypergastrinemia on the ECL cell and oxyntic mucosa, but did not prevent gastric carcinogenesis in female Japanese cotton rats. The effects of vagotomy on gastric carcinogenesis in animal models are conflicting and further studies in patients should be done to clarify the clinically significant effects of vagotomy.
Subject(s)
Carcinogenesis/pathology , Gastric Mucosa/pathology , Gastric Mucosa/surgery , Stomach Neoplasms/pathology , Animals , Chromogranin A/metabolism , Disease Models, Animal , Enterochromaffin-like Cells/metabolism , Female , Gastric Mucosa/innervation , Gastrins/blood , Hydrogen-Ion Concentration , Sigmodontinae , Vagotomy, TruncalABSTRACT
Diabetes mellitus is a complex chronic disease associated with an absolute insulin deficiency in type 1 diabetes (T1D) and a progressive deterioration of ß-cell function in type 2 diabetes (T2D). T2D pathophysiology has numerous defects including incretin deficiency/resistance. Gastrin has demonstrated to be an islet growth factor (like glucagon-like peptide-1, epidermal growth factor, transforming growth factor-α, ) and be able to restore a functional ß-cell mass in diabetic animals. This hormone is likely to stimulate insulin secretion during an ordinary protein-rich meal, this is, to have an incretin-like effect. Proton pump inhibitors (PPIs) can raise serum gastrin concentration significantly and therefore, affect to glucose metabolism through promoting ß-cell regeneration/expansion and also enhancing insulin secretion. The present paper aims to review studies concerning the effect of PPIs on glucose metabolism. Several research groups have recently explored the potential role of this class of drugs on glycemic control, mainly in T2D. The results show antidiabetic properties for the PPIs with a global glucose-lowering power around 0.6-0.7 % points of HbA1c, but the level of evidence for the available literature is still not high. If these data start to become demonstrated in the ongoing clinical trials, PPIs could become a new antidiabetic agent with a good and safe profile for T2D and even useful for T1D, particularly in the area of islet transplantation to preserve ß-cell mass.
Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Gastrin-Secreting Cells/drug effects , Gastrins/metabolism , Gastrointestinal Agents/therapeutic use , Hypoglycemic Agents/therapeutic use , Insulin-Secreting Cells/drug effects , Proton Pump Inhibitors/therapeutic use , Animals , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 1/metabolism , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/metabolism , Enterochromaffin-like Cells/drug effects , Enterochromaffin-like Cells/metabolism , Gastric Emptying/drug effects , Gastrin-Secreting Cells/metabolism , Gastrins/blood , Gastrointestinal Agents/pharmacology , Glucose/metabolism , Humans , Hypoglycemia/prevention & control , Hypoglycemic Agents/pharmacology , Insulin/metabolism , Insulin Secretion , Insulin-Secreting Cells/metabolism , Parietal Cells, Gastric/drug effects , Parietal Cells, Gastric/metabolism , Proton Pump Inhibitors/pharmacology , Somatostatin/metabolism , Somatostatin-Secreting Cells/drug effects , Somatostatin-Secreting Cells/metabolismABSTRACT
BACKGROUND: Sustained acid inhibition with PPI stimulates gastrin secretion, exerting a proliferative drive on enterochromaffin-like cells (ECL cells) of the oxyntic mucosa. It may also accelerate development of gastric gland atrophy in Helicobacter pylori-infected individuals. AIMS: To evaluate gastric exocrine and endocrine cell changes in GERD patients randomised to laparoscopic antireflux surgery (LARS, n = 288) or long-term (5 years) esomeprazole (ESO) treatment (n = 266). METHODS: Antral and corpus biopsies were taken at endoscopy and serum gastrin and chromogranin A levels were assayed, at baseline and after 1, 3 and 5 years' therapy. RESULTS: Biopsies were available at each time point for 158 LARS patients and 180 ESO patients. In H. pylori-infected subjects, antral mucosal inflammation and activity improved significantly (P < 0.001) and stabilised after 3 years on esomeprazole while no change in inflammation was observed after LARS. Oxyntic mucosal inflammation and activity remained stable on esomeprazole but decreased slightly over time after LARS. Neither intestinal metaplasia nor atrophy developed in the oxyntic mucosa. ECL cell density increased significantly after ESO (P < 0.001), corresponding with an increase in circulating gastrin and chromogranin A. After LARS, there was a significant decrease in ECL cell density (P < 0.05), accompanied by a marginal decrease in gastrin and chromogranin. CONCLUSIONS: Antral gastritis improved in H. pylori-infected GERD patients after 5 years on esomeprazole, with little change in laparoscopic antireflux surgery patients, who acted as a control. Despite a continued proliferative drive on enterochromaffin-like cells during esomeprazole treatment, no dysplastic or neoplastic lesions were found and no safety concerns were raised. NCT 00251927.
Subject(s)
Anti-Ulcer Agents/therapeutic use , Enterochromaffin-like Cells/pathology , Esomeprazole/therapeutic use , Gastroesophageal Reflux/drug therapy , Helicobacter Infections/drug therapy , Helicobacter pylori/isolation & purification , Proton Pump Inhibitors/therapeutic use , Adolescent , Adult , Aged , Chromogranin A/blood , Enterochromaffin-like Cells/metabolism , Female , Follow-Up Studies , Gastric Acid/metabolism , Gastric Mucosa/drug effects , Gastric Mucosa/metabolism , Gastrins/blood , Gastroesophageal Reflux/complications , Helicobacter Infections/complications , Humans , Laparoscopy , Male , Middle Aged , Time Factors , Treatment Outcome , Young AdultABSTRACT
Gastric acid secretion is regulated by three primary components that activate the parietal cell: histamine, gastrin, and acetylcholine (ACh). Although much is known about these regulatory components individually, little is known on the interplay of these multiple activators and the degree of regulation they pose on the gastric acid secretion mechanism. We utilized a novel dual-sensing approach, where an iridium oxide sensor was used to monitor pH and a boron-doped diamond electrode was used for the detection of histamine from in vitro guinea pig stomach mucosal sections. Under basal conditions, gastrin was shown to be the main regulatory component of the total acid secretion and directly activated the parietal cell rather than by mediating gastric acid secretion through the release of histamine from the enterochromaffin-like cell, although both pathways were active. Under stimulated conditions with ACh, the gastrin and histamine components of the total acid secretion were not altered compared with levels observed under basal conditions, suggestive that ACh had no direct effect on the enterochromaffin-like cell and G cell. These data identify a new unique approach to investigate the regulation pathways active during acid secretion and the degree that they are utilized to drive total gastric acid secretion. The findings of this study will enhance our understanding on how these signaling mechanisms vary under pathophysiology or therapeutic management.
Subject(s)
Gastric Acid/metabolism , Histamine Release/drug effects , Parietal Cells, Gastric/metabolism , Stomach/physiology , Acetylcholine/pharmacology , Animals , Enterochromaffin-like Cells/metabolism , Gastrin-Secreting Cells/metabolism , Gastrins , Guinea Pigs , Histamine/pharmacology , Hydrogen-Ion Concentration , In Vitro Techniques , Male , Parietal Cells, Gastric/drug effects , Stomach/drug effectsSubject(s)
Neuroendocrine Tumors/pathology , Stomach Neoplasms/pathology , Anti-Ulcer Agents/pharmacology , Biomarkers, Tumor/analysis , Chromogranin A/analysis , Disease Progression , Enterochromaffin-like Cells/chemistry , Enterochromaffin-like Cells/metabolism , Enterochromaffin-like Cells/ultrastructure , Female , Gastric Mucosa/chemistry , Gastric Mucosa/pathology , Gastrins/blood , Gastrins/metabolism , Gastritis, Atrophic/pathology , Histamine Release , Humans , Hyperplasia , Metaplasia , Middle Aged , Neuroendocrine Tumors/chemistry , Neuroendocrine Tumors/classification , Neuroendocrine Tumors/surgery , Parietal Cells, Gastric/drug effects , Parietal Cells, Gastric/metabolism , Stomach Neoplasms/chemistry , Stomach Neoplasms/surgery , Synaptophysin , Vesicular Transport Proteins/analysisABSTRACT
Gastrin, acting through peripheral cholecystokinin (CCK) 2 receptors, is a major hormonal regulator of gastric acid secretion. The effects of gastrin on acid secretion occur both acutely and chronically because gastrin directly stimulates gastric acid secretion and also exerts trophic effects on the enterochromaffin-like and parietal cells that together constitute the acid secretory apparatus of the stomach. Several antagonists that target the CCK2 receptor have been identified and investigated for the treatment of gastroesophageal reflux disease and pancreatic cancer. In this paper, we discuss the contribution of gastrin to these disease pathologies and the data generated to date from clinical studies investigating CCK2 receptor antagonists.